| Multiple Sclerosis |
1 |
1 |
| Clinical Research |
0 |
0.47 |
| Disability |
0 |
0.47 |
| Antihistamine |
0 |
0.99 |
| Cerebrospinal Fluid |
0 |
0.35 |
| Multiple Sclerosis Treatment |
0 |
0.35 |
| Healthcare and Medical Technology |
0 |
0.33 |
| Animal Research |
0 |
0.24 |
| Biomarker |
0 |
0.24 |
| Myelin |
0 |
0.24 |
| Neuromuscular Blocking Agents |
0 |
0.17 |
| Toxicology |
0 |
0.17 |
| Adverse Effects |
0 |
0.12 |
| Allergy |
0 |
0.12 |
| Biomedical Technology |
0 |
0.12 |
| California |
0 |
0.12 |
| Fellowship |
0 |
0.12 |
| Geriatrics |
0 |
0.12 |
| Lung Fibrosis |
0 |
0.12 |
| Metabolism |
0 |
0.12 |
| Multiple Sclerosis Relapse |
0 |
0.12 |
| Muscle |
0 |
0.12 |
| Idiopathic Pulmonary Fibrosis |
0 |
0.08 |